Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity: 2020-2025

Historic Return on Equity for Apellis Pharmaceuticals (APLS) over the last 5 years, with Sep 2025 value amounting to 0.16%.

  • Apellis Pharmaceuticals' Return on Equity rose 116.00% to 0.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.16%, marking a year-over-year increase of 116.00%. This contributed to the annual value of -0.94% for FY2024, which is 197.00% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Return on Equity stood at 0.16%, which was up 111.33% from -1.42% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Return on Equity peaked at 46.97% during Q3 2022, and registered a low of -10.56% during Q4 2021.
  • Moreover, its 3-year median value for Return on Equity was -1.42% (2025), whereas its average is -1.45%.
  • In the last 5 years, Apellis Pharmaceuticals' Return on Equity spiked by 4,216bps in 2022 and then crashed by 4,907bps in 2023.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Return on Equity stood at -10.56% in 2021, then soared by 783bps to -2.73% in 2022, then increased by 26bps to -2.48% in 2023, then surged by 163bps to -0.85% in 2024, then spiked by 116bps to 0.16% in 2025.
  • Its Return on Equity stands at 0.16% for Q3 2025, versus -1.42% for Q2 2025 and -1.14% for Q1 2025.